Reports of Practical Oncology and Radiotherapy · Published 2026-04-27 · DOI 10.5603/rpor.111334
BACKGROUND: Single-fraction stereotactic body radiotherapy (SBRT) has been used to treat lung tumors. However, there is heterogeneity in the prescribed dose. We performed a single-institution, retrospective review to assess the outcomes associated with single-fraction 28 Gy SBRT to cancers in the lung. MATERIALS AND METHODS: A chart review was performed on all patients treated with 28 Gy in 1 fraction to the lung in our institution between February 2022 and April 2023. Patient and tumour characteristics were obtained. Outcomes pertaining to local control, and acute and late toxicities occurring after treatment were obtained from radiological reports and patient charts. RESULTS: 130 patients were reviewed and analyzed. The median follow-up in this cohort was 22 months. 81% of the patients were treated for a primary lung tumour. Estimated Kaplan–Meier 1- and 2-year local control rates were 95.7% (primary: 97.9%, metastases: 89.1%) and 86.9% (primary: 87.6%, metastases: 76.3%), respectively. 21% of patients experienced acute grade 1–2 toxicities, most commonly fatigue and temporary chest wall pain. 18% of patients experienced late grade 1–2 toxicities, most commonly asymptomatic pneumonitis and chest wall pain. There was no reported grade 3 or higher acute or late toxicities. CONCLUSIONS: Our review supports the safety and value of 28 Gy delivered in one fraction. Prospective trials with long-term follow-up are needed to define the role and optimal dose of single-fraction ablative SBRT to lung tumors.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →